retatrutide trial results news today Retatrutide, a new weight loss drug not available on the market yet, is showing promising in trials. @DrLaPook explains it’s doing much more than what current medications can Lilly's triple agonist, retatrutide, delivered

Keep it pretty steady without too many ups and downs

A new study in JAMA Oncology warns that GLP-1 receptor agonists like Ozempic and Mounjaro may raise the risk of kidney cancer, even though they seem to lower the risk of other cancers

Liraglutide-induced injection site reaction

3 Medicaid coverage varies by state

Although the researchers replicate a clinical trial finding of a reduction in heart attacks and strokes among patients with existing cardiovascular disease and chronic kidney disease and a reduction in moderate alcohol consumption risk, they find no statistically significant decline in broader emergency department visits or in any major diagnostic category

GLP1 treatments such as semaglutide (Wegovy) Dualagonists such as tirzepatide (Mounjaro) Noninjectable options such as orlistat